Navigenics, Inc. helps educate and empower individuals and their physicians with knowledge of their genetic predispositions, and then motivates them to act on the information to prevent the onset of disease, achieve earlier diagnosis, appropriately manage disease, or otherwise lessen its impact. Navigenics' lead investors are Kleiner Perkins Caufield and Byers, Sequoia Capital and MDV-Mohr Davidow Ventures.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Navigenics or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.
Our mission is to improve the way startup employees are paid by unlocking the value of their equity compensation in a way that benefits all key players: the shareholder, the company, and the investor.
Equity securities are offered through EquityZen Securities LLC. Check the background of this firm on FINRA's BrokerCheck.
© 2019 EquityZen Inc. All rights reserved.